UI Hospitals and Clinics
A 6-Month, Multicenter, Randomized, Open Label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in Patients with Type 1 Diabetes Mellitus with a 6-month Safety Extension Period
Adults with type 1 diabetes are invited to participate in a research study to compare the safety, effectiveness, & tolerability of new more concentrated form of insulin glargine with the currently marketed form known as Lantus® in adults with type 1 diabetes. There are 10 on-site study visits over an approximate 12 month period.
Julie Coffey at 319-353-6070 or email@example.com
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.